Clinical Trial Update: Phase 1 Study of CLR 125 in Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of CLR 125 for triple-negative breast cancer is currently recruiting, representing an early clinical investigation by Cellectar Biosciences.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CLR 125

Snippet

Sponsor: Cellectar Biosciences, Inc. | Conditions: Breast Cancer | Phase 1 | Status: RECRUITING